What is the recommended management of coronary artery disease in a patient with myelodysplastic syndrome, including antiplatelet therapy, revascularization approach, and anemia treatment?

Management of Coronary Artery Disease in Myelodysplastic Syndrome

In patients with MDS and CAD, use standard antiplatelet therapy (aspirin 75-100 mg daily or clopidogrel 75 mg as alternative) for coronary disease management while maintaining platelet counts >20 × 10⁹/L through aggressive anemia treatment with erythropoiesis-stimulating agents (ESAs), recognizing that bleeding risk is substantially elevated but ischemic protection remains the priority in established CAD. 1, 2

Antiplatelet Therapy Strategy

The 2024 ESC guidelines provide clear direction for antiplatelet therapy in chronic coronary syndromes that should be followed in MDS patients with adequate platelet counts 1:

• For patients with prior MI or PCI: Aspirin 75-100 mg daily lifelong after initial DAPT period, or clopidogrel 75 mg daily as a safe alternative 1
• After CABG: Aspirin 75-100 mg daily lifelong 1
• For significant obstructive CAD without prior events: Aspirin 75-100 mg daily lifelong 1

Critical caveat: The bleeding risk is significantly elevated in MDS patients on antithrombotic therapy. Research shows cumulative incidence of major bleeding at 4 years reaches 11.8% with antiplatelet agents versus only 2.8% in untreated MDS patients 3. This bleeding risk is compounded because MDS platelets are dysfunctional, not just reduced in number 4.

Platelet Count Threshold Management

Maintain platelets >20 × 10⁹/L as the minimum threshold for continuing antiplatelet therapy, though this is based on the study inclusion criteria rather than explicit guidelines 3. Below this level, the decision becomes extremely high-risk and requires:

• Daily platelet monitoring
• Immediate access to platelet transfusions
• Consideration of temporary antiplatelet cessation if acute bleeding occurs
• Case-by-case assessment of stent thrombosis risk versus bleeding risk

Post-PCI DAPT Duration

For MDS patients undergoing PCI, follow standard DAPT protocols but consider early de-escalation 1:

• Default strategy: DAPT (aspirin 75-100 mg + clopidogrel 75 mg) for up to 6 months after PCI-stenting
• High bleeding risk patients (which includes most MDS patients): Discontinue DAPT at 1-3 months and continue single antiplatelet therapy 1
• Avoid ticagrelor or prasugrel - these potent P2Y12 inhibitors increase bleeding risk beyond acceptable levels in MDS

Add proton pump inhibitor for gastrointestinal bleeding prophylaxis during any antithrombotic therapy period 1.

Revascularization Approach

PCI is preferred over CABG in MDS patients when anatomically feasible, based on the following reasoning:

• CABG in MDS carries substantial perioperative risk due to pancytopenia 5
• The single case report of successful CABG required extensive perioperative support including G-CSF, RBC transfusions, and platelet transfusions 5
• PCI allows for shorter DAPT duration (1-6 months) compared to the indefinite aspirin requirement post-CABG 1
• Drug-eluting stents are acceptable despite the case report of pericardial tamponade, as this represents a rare complication 4

If CABG is unavoidable:

• Preoperative G-CSF administration
• Aggressive RBC and platelet transfusion support perioperatively
• Close monitoring for infection and bleeding complications 5

Anemia Management Priority

Aggressive treatment of anemia in MDS patients with CAD is essential because lower ferritin levels correlate with increased vascular events 6. This finding suggests that undertransfusion may worsen cardiovascular outcomes.

Lower-Risk MDS Without del(5q)

First-line: ESAs (erythropoietin 30,000-80,000 units weekly or darbepoetin 150-300 mcg) when baseline EPO <500 U/L and transfusion requirement is absent or limited 2:

• Response rate: 40-60%
• Response occurs within 8-12 weeks
• Add G-CSF if inadequate response 2

Transfusion support: Maintain hemoglobin adequate for cardiac perfusion - do not allow symptomatic anemia to persist while awaiting ESA response

Lower-Risk MDS With del(5q)

First-line: ESAs have lower response rates in del(5q) patients 2

Second-line: Lenalidomide 10 mg/day for 3 weeks every 4 weeks achieves 60-65% response rate with median RBC transfusion independence of 2-2.5 years 2

• Monitor closely for grade 3-4 neutropenia and thrombocytopenia (occurs in ~60%)
• Check for TP53 mutations which confer resistance 2

Transfusion-Dependent Patients

Luspatercept shows promising results in RBC transfusion-dependent lower-risk MDS 2

Imetelstat was approved in 2024 for transfusion-dependent lower-risk MDS 7

Risk Stratification Considerations

ASXL1 mutations increase vascular disease risk in MDS patients 6. While no specific preventive guidelines exist, these patients warrant:

• More aggressive cardiovascular risk factor management
• Lower threshold for cardiology consultation
• Consideration of standard lipid-lowering therapy per ESC guidelines (LDL-C <1.4 mmol/L with high-intensity statin) 1

Trisomy 8 in low-risk MDS appears protective against vascular events 6, though this should not alter standard CAD management.

Anticoagulation in Special Circumstances

If MDS patients with CAD require anticoagulation for atrial fibrillation or other indications 1:

• Prefer DOAC over warfarin (unless contraindicated)
• After PCI: Triple therapy with early aspirin cessation (≤1 week), then continue OAC + clopidogrel for up to 6 months, followed by OAC alone
• Avoid ticagrelor or prasugrel as part of triple therapy

Monitoring Protocol

• Platelet counts: At minimum weekly during DAPT, twice weekly if counts 20-50 × 10⁹/L
• Hemoglobin: Every 2-4 weeks, more frequently if symptomatic
• Bleeding assessment: At every visit with specific questioning about mucosal bleeding, bruising, hematuria
• Bone marrow surveillance: Per standard MDS guidelines to monitor for clonal evolution 2